Fighting
Solid Tumors With
Smart LBP Technology
Delivering hope to patients with
advanced pancreatic cancer and
other aggressive solid tumors.
Saltikva
Saltikva is our lead program in patients with Stage 4, metastatic pancreatic cancer. The Phase 2 results showed that Saltikva was able to dramatically reduce tumor markers, tumor burden, and increase Progression Free Survival and Overall Survival when administered with modified FOLFIRINOX. No serious adverse reactions were caused by Saltikva in the clinical study.
​​
Saltikva will soon enter advanced clinical studies in other aggressive solid tumors.
Testimonials
Safe &
Effective
Over 20 years of research, we have developed a safe vector to deliver the micro-factory for the production of cytokines within the tumor. The production of target drugs intra-tumorally avoids potential complications and toxicity associated with the systemic administration of the same cytokines. Additionally, our LBP vectors cause tumor destruction by two other, recognized modes of action, rendering our technology both safe and effective.
Testimonials
March 2025
Saltikva Patient Interview
Behind every therapy is a story.
This is one of them.​
Regulatory &
Expanded Access
Saltikva is not yet an approved pharmaceutical product. Salspera is currently planning pivotal trials for approval purposes.
​
Saltikva has been awarded Orphan Drug and Fast Track Designations by the US FDA.
​
Salspera will consider all compassionate care requests under Expanded Access, depending on the review of patient criteria and other factors such as drug availability.
​
Salspera Osteosarcoma Program was awarded Orphan Drug Designation by US FDA (November 2025)
​
Leadership
Salspera is managed by an expert team along with a Medical Advisory Panel and Business Advisory Panel.
​
Salspera is opperationally supported by external advisors, consultants and service providers to professionally manage the development of the technology, products and the business.
Eddie Moradian, PhD, Chief Executive Officer
​
Eddie Moradian is a seasoned biotech and life sciences executive having founded / co-founded 10 biotech companies over 30 years He is an experienced investor and operational chief executive of biotech companies involved in the life science research and early-stage drug development sectors. He has extensive experience in bringing advanced R&D to market.Eddie Moradian holds a PhD Degree from the Swiss Federal Institute of Technology in Zurich, Switzerland
Dan Saltzman, MD, PhD Chief Medical Officer
Dan Saltzman is the originator of the technology platform, which is the basis of Salspera today. He is a thought leader who brings leadership and experience in treating patients facing terminal diseases. Dan Saltzman is Chief of Pediatric Surgery at the University of Minnesota. Amongst his many accomplishments was the separation of conjoined twins in 2022. He earned his MD and PhD degrees from the University of Minnesota
News
June, 2025
Salspera presents results from its Phase 2 study of Saltikva in patients with Stage 4 metastatic pancreatic cancer at the annual meeting of the American Society for Clinical Oncology in Chicago, IL.
July, 2025
Salspera begins formal planning of its Phase 2 studies in Osteosarcoma and metastatic colorectal cancer. These programs will follow Salspera's Phase 3 study of Saltikva in patients with metastatic pancreatic cancer.
September, 2025
Salspera expands its Scientific Advisory Board with oncology thought leaders and creates a new Board of Directors to guide its rapid progress into the next phase clinical studies.
November, 2025
Salspera receives Orphan Drug Designation from FDA for the application of Saltikva in Osteosarcoma. This important designation follows the Orphan Drug Designation and Fast Track Designation received for Stage 4 pancreatic cancer in 2022.
January, 2026
Salspera's new publication is accepted by the Cancer Immunology, Immunotherapy. The new manuscript is a comprehensive presentation of the groundbreaking results obtained in the Phase 2 study and joins a list of 30+ publications detailing results obtained with Saltikva in all phases of development.